A PROLIFERATION-INDUCING LIGAND: A NEW BIOMARKER FOR NON-SMALL CELL LUNG CANCER

REFERENCES

• Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer J L, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188: 1185–1190
   PubMed Web of Science ®Google Scholar
• Pradet-Balade B, Medema J P, Lopez-Fraqa M, Lozano J C, Kolfschoten G M, Picard A, et al. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 2002; 21: 5711–5720
   PubMed Web of Science ®Google Scholar
• Ware C F. APRIL and BAFF connect autoimmunity and cancer. J Exp Med 2000; 192: 35–38
   Web of Science ®Google Scholar
• Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nature Immunol 2000; 1: 252–256
   PubMed Web of Science ®Google Scholar
• Kelly K, Manos E, Jensen G, Nadauld L, Jones D A. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 2000; 60: 1021–1027
   PubMed Web of Science ®Google Scholar
• Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, et al. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 2001; 8: 403–410
   PubMed Web of Science ®Google Scholar
• Novak A J, Bram R J, Kay N E, Jelinek D F. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100: 2973–2979
   PubMed Web of Science ®Google Scholar
• Marsters S A, Yan M, Pitti R M, Haas P E, Dixit V M, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785–788
   PubMed Web of Science ®Google Scholar
• Litinskiy M B, Nardelli B, Hilbert D M, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822–829
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Ni J, Zhai Y, Yu G L, Aggarwal B B. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274: 15978–15981
   PubMed Web of Science ®Google Scholar
• Nardelli B, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198–204
   PubMed Web of Science ®Google Scholar
• Moreaux J, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021–1030
   PubMed Web of Science ®Google Scholar
• Deshayes F, Lapree G, Portier A, Richard Y, Pencalet P, Mahieu-Caputo D, et al. Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene 2004; 15: 3005–3012
   Web of Science ®Google Scholar
• Okano H, Shiraki K, Yamanaka Y, Inoue H, Kawakita T, Saitou Y, et al. Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization. World J Gastroenterol 2005; 11: 4650–4654
   PubMed Web of Science ®Google Scholar
• Zhang D-l, Ju S-Q, Shi J, Wang H-M, Ni H-B, Su J-Y, et al. Measurement of the expression level of APRIL and its receptors in liver cancer tissue by real-time fluorescence quantitative method. Chin J Lab Med 2005; 28: 433–436
   Google Scholar
• Mhawech-Fauceqlia P, Kaya G, Sauter G, Mckee T, Donze O, Schwaller J, et al. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 2006; 80: 697–704
   PubMed Web of Science ®Google Scholar
• Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• Fielding P, Turnbull L, Prime W, Walshaw M, Field J K. Heterogenous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin Cancer Res 1999; 5: 4048–4052
   PubMed Web of Science ®Google Scholar
• Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997; 89: 1609–1615
   PubMed Web of Science ®Google Scholar
• Jang S J, Soria J C, Wang L, Hassan K A, Morice R C, Walsh G L, et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 2002; 61: 7959–7963
   Web of Science ®Google Scholar
• Nelson H H, Christiani D C, Mark E J, Wiencke J K, Wain J C, Kelsey K T. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91: 2032–2038
   PubMed Web of Science ®Google Scholar
• Lacroix J, Becker H D, Woerner S M, Rittgen W, Drings P, von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-spefic RT-PCR. Int J Cancer 2001; 92: 1–8
   PubMed Web of Science ®Google Scholar
• Tora M, Barbera V M, Real F X. Detection of HuD transcripts by means of reverse transcriptase and polymerase chain reaction: implications for the detection of minimal residual disease in patients with small cell lung cancer. Cancer Lett 2000; 161: 157–164
   PubMed Web of Science ®Google Scholar
• Ahrendt S A, Decker P A, Doffek K, Wang B, Xu L, Demeure M J, et al. Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer. Cancer Res 2000; 60: 2488–2491
   PubMed Web of Science ®Google Scholar
• Pizzichini E, Pizzichini M MM, Efthimiadis A, et al. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J 1996; 9: 1174–1180
   PubMed Web of Science ®Google Scholar
• Allred D C, Harvey J M, Berardo M, Clark G M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155–168
   PubMed Web of Science ®Google Scholar
• Shi J, Zhang D, Cui Z, et al. Expression of a proliferation-inducing ligand and its receptors in different tumors and its significance. Lab Med 2007; 22: 150–154
   Google Scholar
• Belinsky S A, Klinge D M, Dekker J D, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005; 11: 6505–6511
   PubMed Web of Science ®Google Scholar
• Dong D Q, Yang Y H, Xue D Y, et al. Expression of survivin mRNA of sputum and pleural effusions in human lung cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31: 848–852
   PubMedGoogle Scholar
• Tanabe H, Yagihashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung cancer 2004; 46: 299–304
   PubMed Web of Science ®Google Scholar
• Destro A, Bianchi P, Alloisio M, Laghi L, Di Gioia S, Malesci A, et al. K-ras and p16(INK4A) alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 2004; 44: 23–32
   PubMed Web of Science ®Google Scholar
• Keohavong P, Gao W M, Zheng K C, Mady H, Lan Q, Melhem M, et al. Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Anal Biochem 2004; 324: 92–99
   PubMed Web of Science ®Google Scholar
• Dorland's Illustrated Medical Dictionary, 27th ed. WB Saunders, Philadelphia 1988; 1570
   Google Scholar
• Choi Y D, Han C W, Kim J H, Oh I J, Lee J S, Nam J H, et al. Effectiveness of sputum cytology using ThinPrep method for evaluation of lung cancer. Diagn Cytopathol 2008; 36: 167–171
   PubMed Web of Science ®Google Scholar